A detailed history of Pacer Advisors, Inc. transactions in 89bio, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 816 shares of ETNB stock, worth $6,976. This represents 0.0% of its overall portfolio holdings.

Number of Shares
816
Previous 2,146 61.98%
Holding current value
$6,976
Previous $24,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$7.31 - $10.9 $9,722 - $14,497
-1,330 Reduced 61.98%
816 $6,000
Q1 2024

May 10, 2024

BUY
$8.13 - $13.77 $17,446 - $29,550
2,146 New
2,146 $24,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $397M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.